Comparing the current results to its competitors, Vor Biopharma Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 18.28 %, recorded in the same quarter.
Vor Biopharma Inc 's Comment on Competition and Industry Peers
The company operates in the autoimmune therapy sector, developing various treatment types including fusion proteins (atacicept, povetacicept), monoclonal antibodies, other biologics, CAR T cells, and small molecules. Competitors in this field include Alexion, Amgen, Argenx, Dianthus, Johnson & Johnson, UCB, and Vertex, which have products either marketed or in development. There is a risk that these competitors may obtain regulatory approval before the company or develop therapies that are safer or more effective, potentially affecting the company's financial condition and commercialization efforts.
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid™ platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body's natural protein degradation machinery.
Beam Therapeutics Inc's business model revolves around developing precision genetic medicines using base editing technology. They aim to address genetic diseases by making precise edits to a patient's DNA at the molecular level, providing potential treatments that are highly targeted and minimally invasive.
Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.
Voyager Therapeutics Inc. is a biopharmaceutical company that focuses on the development of gene therapies to treat severe neurological diseases. Their business model revolves around research, development, and commercialization of innovative treatments using viral gene therapy technology.
Sources:
Vor Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vor Biopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
